Rise of Generics & Biosimilars Fuels New Fill Lines While originator drugs still account for most volumes, generics and biosimilars are rapidly expanding, requiring CDMOs with flexible, multiformat fill lines and faster changeovers. Source: https://www.marketresearchfuture.com/reports/fill-finish-pharmaceutical-contract-manufacturing-market-31246